Insulin Resistance Is Associated with Increased Circulating Level of Thrombin-Activatable Fibrinolysis Inhibitor in Type 2 Diabetic Patients

2002 ◽  
Vol 87 (2) ◽  
pp. 660-665 ◽  
Author(s):  
Yasuko Hori ◽  
Esteban C. Gabazza ◽  
Yukata Yano ◽  
Akira Katsuki ◽  
Koji Suzuki ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Plasma Levels ◽  
Common Finding ◽  
Diabetic Patients ◽  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Type 2 Diabetic Patients ◽  
Visceral Fat Area ◽  
Type 2 Dm ◽  
Fibrinolysis Inhibitor

Hypofibrinolysis is a common finding in patients with diabetes mellitus (DM) and obesity and a risk factor for the development of cardiovascular disease. Recently, a new potent inhibitor of fibrinolysis, the thrombin-activatable fibrinolysis inhibitor (TAFI) has been isolated and characterized from human plasma. The present study was undertaken to assess the activity and circulating level of TAFI and its relation to fibrinolytic function and obesity in patients with type 2 DM. Fifty-seven patients with type 2 DM (38 men, 19 women) were enrolled in this study. DM patients were categorized in age-matched obese [body mass index (BMI) ≥ 25] and nonobese (BMI < 25) groups. The plasma concentration and activity of TAFI were significantly (P < 0.05) higher in DM patients than in healthy controls. The plasma levels and activity of TAFI were significantly (P < 0.05) elevated in obese DM patients compared with nonobese DM and nonobese healthy subjects. RT-PCR demonstrated the expression of TAFI in human adipose tissue and in human endothelial cells. The plasma levels of TAFI were independently and significantly correlated with glucose intolerance (HbA1c), with obesity (BMI, visceral fat area), and with an indicator of insulin resistance (glucose infusion rate). This study showed that increased circulating level of TAFI may be an important causative factor of hypofibrinolysis in patients with type 2 diabetes, obesity and insulin resistance.

Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients

Metabolism ◽  
2006 ◽  
Vol 55 (11) ◽  
pp. 1437-1442 ◽  
Author(s):  
Mercedes Rigla ◽  
Ana Maria Wägner ◽  
Montserrat Borrell ◽  
José Mateo ◽  
Jordi Foncuberta ◽  
...  
Keyword(s):  
Endothelial Dysfunction ◽  
Diabetic Patients ◽  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Type 2 Diabetic Patients ◽  
Fibrinolysis Inhibitor ◽  
Type 2 Diabetic

scholarly journals Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients

2004 ◽  
Vol 181 (3) ◽  
pp. 413-417 ◽  
Author(s):  
T Adachi ◽  
M Inoue ◽  
H Hara ◽  
E Maehata ◽  
S Suzuki
Keyword(s):  
Insulin Resistance ◽  
Superoxide Dismutase ◽  
Plasma Levels ◽  
Tnf Alpha ◽  
Diabetic Patients ◽  
Extracellular Superoxide Dismutase ◽  
Type 2 Diabetic Patients ◽  
Relationship Of ◽  
Type 2 Diabetic

Extracellular-superoxide dismutase (EC-SOD) is a secretory glycoprotein located in blood vessel walls at high levels and may be important in the antioxidant capability of vascular walls. The aim of this study was to assess plasma levels of EC-SOD and to evaluate the relationship of the EC-SOD level with insulin resistance in type 2 diabetic patients. We determined plasma EC-SOD in 122 patients and found for the first time that the EC-SOD level was strongly and positively related to adiponectin (r=0.503, P < 0.001), and significantly and inversely related to fasting plasma glucose (FPG) (r=-0.209, P=0.022), body-mass index (BMI) (r=-0.187, P=0.040) and homeostasis model assessment-insulin resistance index (HOMA-R) (r=-0.190, P=0.039). Stepwise-multiple regression analysis also showed a significant influence of adiponectin (F=33.27) on the EC-SOD level. Administration of pioglitazone to 19 diabetic patients significantly increased the plasma levels of EC-SOD (69.9+/-19.3 ng/ml to 97.4+/-25.9 ng/ml; P < 0.0001) and adiponectin, while it decreased tumor necrosis factor-alpha (TNF-alpha). The present observations suggest that factors related to the pathogenesis of insulin resistance play an important role in the regulation of the plasma EC-SOD concentration. It is possible that the increase in the EC-SOD level by pioglitazone administration in diabetic patients is due to a decline of TNF-alpha, which is known to suppress EC-SOD expression.

scholarly journals Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus

2004 ◽  
pp. 573-577 ◽  
Author(s):  
A Katsuki ◽  
H Urakawa ◽  
EC Gabazza ◽  
S Murashima ◽  
K Nakatani ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Levels ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Abdominal Adiposity ◽  
Type 2 Diabetic Patients

OBJECTIVE: To investigate the relationship between the circulating level of active ghrelin and abdominal adiposity, serum levels of insulin or insulin resistance in patients with type 2 diabetes mellitus. DESIGN: We measured the plasma levels of the active form of ghrelin in 18 obese and 18 nonobese patients with type 2 diabetes mellitus using a radioimmunoassay (RIA) kit. Body fat accumulation was measured by computed tomography (CT) and insulin resistance by the glucose infusion rate (GIR) during an euglycemic hyperinsulinemic clamp study. RESULTS: Plasma levels of ghrelin in obese patients with type 2 diabetes mellitus were significantly decreased compared with nonobese patients. There were significant correlations between the plasma levels of ghrelin and BMI (r=-0.505, P<0.01), visceral (r=-0.444, P<0.01), subcutaneous (r=-0.506, P<0.01) and total (r=-0.534, P<0.01) fat area, serum levels of insulin (r=-0.513, P<0.01) or GIR (r=0.478, P<0.01) in type 2 diabetic patients. The plasma level of ghrelin was significantly associated with serum levels of insulin (F=8.468, P<0.05) or GIR (F=8.522, P<0.05) after adjustment for BMI in patients with type 2 diabetes mellitus. CONCLUSIONS: Decreased plasma levels of active ghrelin are significantly associated with abdominal adiposity, hyperinsulinemia and insulin resistance in type 2 diabetic patients. Hyperinsulinemia associated with insulin resistance may suppress plasma levels of active ghrelin in patients with type 2 diabetes mellitus.

scholarly journals The Relation of IGF-1 and Insulin Resistance in a Sample of Iraqi Obese Type 2 Diabetic Patients with Macrovascular Disease

2012 ◽  
Vol 9 (4) ◽  
pp. 656-662
Author(s):  
Baghdad Science Journal
Keyword(s):  
Insulin Resistance ◽  
Body Mass Index ◽  
Body Mass ◽  
Diabetic Patients ◽  
Model Assessment ◽  
Type 2 Diabetic Patients ◽  
Type 2 Dm ◽  
Increased Risk ◽  
Type 2 Diabetic

Type 2 diabetes mellitus(T2DM) is a metabolic disease that is associated with an increased risk for atherosclerosis by 2-4 folds than in non- diabetics. In general population, low IGF-1 has been associated with higher prevalence of cardiovascular disease and mortality .This study aims to find out the relationship between IGF-1 level and other biochemical markers such as Homeostasis Model Assessment insulin resistance(HOMAIR) and Body Mass Index(BMI) in type 2 diabetic patients . This study includes (82) patients (40 females and 42 males) with age range (40-75) years,(34) non obese diabetic patients and (48) obese diabetic patients. The non obese individuals considered as a controls group, all controls and patients groups with type 2 DM, ischemic heart disease and hypertension, and free from other disease by history and clinical exam .The results showed that serum IGF-1 levels were lower in obese diabetic patients than non obese.HOMAIR has been found to be significantly higher in obese than non obese diabetic patients ,there is negative correlation between IGF-1 and HOMAIR. Body mass index (BMI) was in positive correlation with HOMAIR and innegativecorrelationwithIGF-1. Conclusion of this study was the serum level of IGF-1 is significantly lower in obese than non obese type 2 DM , but HOMA IR is significantly higher in obese diabetic subjects .

scholarly journals Frequency of Hyperlipidemia in the Diagnosed Type 2 Diabetic Patients

2021 ◽  
Vol 8 (1) ◽  
pp. 25-30
Author(s):  
Shama Iqbal ◽  
Ambreen Gul ◽  
Rashid Ahmad ◽  
Momina Haq ◽  
Sara Maryam ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Descriptive Study ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Primary Event ◽  
Type 2 Diabetic Patients ◽  
Type 2 Dm ◽  
The World ◽  
Type 2 Diabetic

OBJECTIVES: The primary event in the development of type-2 diabetes is directly associated with lipid metabolism derangement occurring due to insulin resistance. The aim of this study was to find out the prevalence of hyperlipidemia in the newly diagnosed type-2 DM. METHODOLOGY: This hospital based descriptive study was conducted in the year 2018 to 2019, on 100 newly diagnosed type-2 diabetic patients attending medical O.P.D or admitted in medial wards of Naseer Ullah Khan Babar Memorial Hospital Kohat Road Peshawar. RESULTS: The incidence of hyperlipidemia in newly diagnosed diabetic patients was 29%. About 71% patients were having normal lipid profile. Our study also revealed that the frequency of hyperlipidemia increases with age. Half of the patients having age more than 60 years developed hyperlipidemia. Among hyperlipidemic patients, hypercholesterolemia was present in 36% and hypertriglyceridemia in 64% patients CONCLUSION: The study suggests that hyperlipidemia is very common in newly diagnosed type-2 diabetic patients in this part of the world.  

Sign in / Sign up

Export Citation Format

Share Document